Strategies for the empirical management of infection in cancer patients with emphasis on the emergence of resistant gram-negative bacteria

Critical Reviews in Oncology/Hematology

Volumn 92, Issue 3, 2014, Pages 268-278

  Klastersky, Jean ^a   Georgala, Aspasia ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Aminoglycosides; Antibiotics; Beta lactams; Cancer patients; Combination; Gram negative bacteria; Resistance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIFAMPICIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE LEUKEMIA; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; DRUG POTENTIATION; ESCHERICHIA COLI; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM NEGATIVE SEPSIS; HUMAN; INFECTION; INFECTION CONTROL; INFECTION PREVENTION; LOW RISK PATIENT; MASCC PREDICTIVE INDEX SCORE; MONOTHERAPY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PNEUMONIA; REVIEW; SCORING SYSTEM; SEPSIS; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; NEOPLASM; RISK FACTOR;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; NEOPLASMS; RISK FACTORS;

EID: 84912529651     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.06.002     Document Type: Review

References (83)

1. Bodey G.P., Buckley M., Sathe Y.S., et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966, 64:328-340.
2. Klastersky J., Awada A., Paesmans M., et al. Febrile neutropenia: a critical review of the initial management. Crit Rev Oncol Hematol 2011, 78:185-194.
3. Weycker D., Malin J., Edelsberg J., et al. Cost of neutropenic complications of chemotherapy. Ann Oncol 2008, 19:454-460.
4. McCabe W.R., Jackson G.G. Gram-negative bacteremia. Int Arch Med 1962, 110:92-100.
5. Klastersky J., Ameye L., Maertens J., et al. Bacteremia in febrile neutropenia cancer patients. Int J Antimicrob Agents 2007, 30S:S51-S59.
6. Schimpff S., Satterlee W., Young V.M., et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971, 284:1061-1065.
7. Klastersky J. Why empirical therapy?. J Antimicrob Chemother 2009, 63:i14-i15.
8. Klastersky J., Cappel R., Debusscher L. Evaluation of gentamicin with carbenicillin in infections due to gram-negative bacilli. Curr Ther Res 1971, 13:174-181.
9. Jawetz E. The use of combinations of antimicrobial drugs. Annu Rev Pharmacol 1968, 8:151-170.
10. Klastersky J., Cappel R., Daneau D. Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob Agents Chemother 1972, 2:470-475.
11. Klastersky J., Daneau D., Swings G., et al. Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J Infect Dis 1974, 129:187-193.
12. De Jongh C., Joshi J.H., Newman K., et al. Antibiotic synergism response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med 1986, 80:96-100.
13. The EORTC International Antimicrobial Therapy Cooperative Group: ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987, 317:1692-1698.
14. Tamura K., Imajo K., Akiyama N., et al. Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. Clin Infect Dis 2004, 39:S15-S24.
15. Ronit M., Mical P., Elphick H., et al. Clinical implications of β-lactam-aminoglycoside synergism: systematic review of randomized trials. Int J Antimicrob Agents 2011, 37:491-503.
16. Furno P., Bucaneve G., Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenia patients: a meta-analysis. Lancet 2002, 2:231-242.
17. Freifeld A.G., Bow E.J., Sepkowitz K.A., et al. Executive summary: clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011, 52:427-431.
18. De Naurois J., Novitzky-Basso I., Gill M.J., et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 2010, 21:252-256.
19. Paul M., Yahav D., Bivas A., et al. Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev 2010, 11:CD005197.
20. Cometta A., Kern W.V., De Bock R., et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003, 37:382-389.
21. Feld R. Bloodstream infections in cancer patients with febrile neutropenia. Int J Antimicrob Agents 2008, 32:S30-S33.
22. Klastersky J., Paesmans M., Rubenstein E.B., et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenia cancer patients. J Clin Oncol 2000, 18:3038-3051.
23. Hui E.P., Leung L.K.S., Poon T.C.W., et al. Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. Support Care Cancer 2011, 19:1625-1635.
24. Innes H., Lim S.L., Hall A., et al. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer 2008, 16:485-491.
25. Uys A., Rapoport B.L., Fickl H., et al. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procacitonin, C-reactive protein, serum amyloid A, and interleukins-1β, -6, -8 and -10. Eur J Cancer Care 2007, 16:475-483.
26. Paesmans M., Klastersky, Maertens J., et al. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?. Support Care Cancer 2011, 19:1001-1008.
27. Moreau M., Klastersky J., Schwarzbold A., et al. A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol 2009, 20:513-519.
28. Park Y., Sik Kim D., Jong Park S., et al. The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease. Leuk Res 2010, 34:294-300.
29. Ahn S., Lee Y.-S., Chun Y.-H., et al. Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer 2011, 19:1151-1158.
30. Kern W.V., Cometta A., De Bock R., et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999, 341:312-318.
31. Sebban C., Dussart S., Fuhrmann C., et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer 2008, 16:1017-1023.
32. Innes H.E., Smith D.B., O'Reilly S.M., et al. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomized controlled single centre study. Br J Cancer 2003, 89:43-49.
33. Klastersky J., Paesmans M., Georgala A., et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 2006, 24:4129-4134.
34. André S., Taboulet P., Elie C., et al. Febrile neutropenia in French emergency departments: results of a prospective multicentre survey. Critical Care 2010, 14:1-11.
35. Mato A.R., Luger S.M., Heitjan D.F., et al. Elevation in serum lactate at the time of febrile neutropenia (FN) in hemodynamically-stable patients with hematologic malignancies (HM) is associated with the development of septic shock within 48hours. Cancer Biol Ther 2010, 9:585-589.
36. Courtney D.M., Aldeen A.Z., Gorman S.M.
37. Berghmans T., Paesmans M., Lafitte J.J., et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. Support Care Cancer 2002, 10:181-188.
38. Al-Tanbal H., Al Humaidan H., Al-Nounou R., et al. The value and practicality of granulocyte transfusion: a single oncology centre. Transfus Med 2010, 20:160-168.
39. Wingard J.R., Elmongy M. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics. Crit Rev Oncol Hematol 2009, 72:144-154.
40. Kuderer N.M., Dale D.C., Crawford J., et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007, 25:3158-3167.
41. Cooper K.L., Madane J., Whyte S., et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011, 23(11):404.
42. Smith T., Khatcheressian J., Lyman G.H., Ozer H., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205.
43. Aapro M., Bohlius J., Cameron D., et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011, 47:8-32.
44. Schlesinger A., Paul M., Gafter-Gvili A., et al. Infection-control interventions for cancer patients after chemotherapy: a systematic review and meta-analysis. Lancet 2009, 9:97-107.
45. EORTC International Antimicrobial Therapy Project Group Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. J Infect Dis 1984, 150:372-379.
46. Cullen M., Steven N., Billingham L., et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005, 353:988-998.
47. Bucaneve G., Micozzi A., Menichetti F., et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005, 353:977-987.
48. Kern W.V., Andriof E., Oethinger M., et al. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994, 38:681-687.
49. Kern W.V., Klose K., Jellen-Ritter A.S., et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005, 24:111-118.
50. Cattaneo C., Quaresmini G., Casari S., et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 2008, 61:721-728.
51. Lautenbach E., Metlay J.P., Bilker W.B., et al. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infection: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005, 41:923-929.
52. Hooper D.C. Mechanisms of fluoroquinolone resistance. Drug Resist Updat 1999, 2:38-55.
53. Chenia H.Y., Pillay B., Pillay D. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. J Antimicrob Chemother 2006, 58:1274-1278.
54. Jacoby G.A. Mechanisms of resistance to quinolones. Clin Infect Dis 2005, 41:S120-S126.
55. Robicsek A., Jacoby G.A., Hooper D.C. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006 Oct, 6:629-640.
56. Pitout J.D., Laupland K.B. Extended-spectrum B-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8:159-166.
57. Garnica M., Maiolino A., Nucci M. Factors associated with bacteremia due to multidrug-resistant gram-negative bacilli in hematopoietic stem cell transplant recipients. Braz J Med Res 2009, 42:289-293.
58. NCCN guidelines. Available from:. http://www.nccn.org/.
59. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15(Oct (10)):1143-1238.
60. Novak R., Charpentier E., Braun J.S., et al. Signal transduction by a death signal peptide: uncovering the mechanism of bacterial killing by penicillin. Mol Cell 2000, 5:49-57.
61. Palumbi S.R. Humans as the world's greatest evolutionary force. Science 2001, 293:1786-1790.
62. Tomasz A. Antibiotic resistance in streptococcus pneumonia. Clin Infect Dis 1997, 24(Suppl. 1):S85-S88.
63. Jacobson K.L., Cohen S.H., Inciardi J.F., et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms. Clin Infect Dis 1995, 21:1107-1113.
64. Katsanis G.P., Spargo J., Ferraro M.J., et al. Detection of Klebsiella pneumonia and Escherichia coli strains producing extended-spectrum lactamases. J Clin Microbiol 1994, 32:691-696.
65. Papanicolaou G.A., Medeiros A.A., Jacoby G.A. Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lacatms in clinical isolates of Klebsiella pneumonia. Antimicrob Agents Chemother 1990 Nov, 34(11):2200-2209.
66. Queenan A.M., Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007, 20:440-458.
67. Watanabe M., Iyobe S., Inoue M., et al. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991, 35:147-151.
68. CRE in Europe - Current European situation and future plans for control. Available from:. http://www.ecdc.europa.eu/.
69. Olsen S.J., DeBess E.E., McGivern T.E., et al. A nosocomial outbreak of fluoroquinolone-resistant salmonella infection. N Engl J Med 2001, 344:1572-1579.
70. Garau J., Xercavins M., Rodriguez-Carballeira M., et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999, 43:2739-2741.
71. Arias C.A., Murray B.E. Antibiotic-resistant bugs in the 21st century - a clinical super challenge. N Engl J Med 2009, 360:439-443.
72. Peleg A.Y., Hooper D.C. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 2010, 362:1804-1813.
73. Li J., Turnidge J., Milne R., et al. In vitro pharmacodynamics properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001, 45:781-785.
74. From A.H., Fong J.S., Good R.A. Polymyxin B sulfate modification of bacterial endotoxin: effects of the development of endotoxin shock in dogs. Infect Immun 1979, 23:660-664.
75. Dougan G., Phil D. Does the Trojan horse have an Achille's heel?. N Engl J Med 2009, 360:83-84.
76. Huston A., Lyman G.H. Agents under investigation for the treatment and prevention of neutropenia. Expert Opin Invest Drug 2007, 16:1831-1840.
77. Levy O. Antimicrobial proteins and peptides: anti-infective molecules of mammalian leukocytes. J Leukoc Biol 2004, 76:1-12.
78. Marr J.J., Moffet H.L., Kunin C.M. Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the Infectious Diseases Society of America. J Infect Dis 1988, 157:869-876.
79. Shlaes D.M., Gerding D.N., John J.F., et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997, 25:584-599.
80. Evans R.S., Pestotnik S.L., Classen D.C., et al. A computer-assisted management for antibiotics and other antiinfective agents. N Engl J Med 1998, 338(Jan (4)):232-238.
81. Dellit T.H., Owens R.C., McGowan J.E., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177.
82. Hermsen E.D., VanSchooneveld T.C., Sayles H. Implementation of a clinical decision support system for antimicrobial stewardship. Infect Control Hosp Epidemiol 2012, 33:412-415.
83. Fishman N.O. ICAAC 2012, San Francisco, California 1922.